Chiesi Group Company Profile

02:09 EDT 30th July 2015 | BioPortfolio

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,700 employees, of whom 300 are involved in research and development activities.

Chiesi’s technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures.

Chiesi's formula for success is based on a peculiar approach that allows to combine factors often thought of as opposites in the pharmaceutical industry – such as research and ethics, technology and humanity, commitment to results and concern for individuals, reliability and empathy – while encouraging innovation at all levels. The final goal is the creation of value through innovation.

Location

Chiesi Farmaceutici S.p.A.Via Palermo, 26/A,
Parma
43100
Italy

Contact

Phone: 39 0521 2791
Fax: 39 0521 774468
Email: info@chiesigroup.com


News Articles [203 Associated News Articles listed on BioPortfolio]

Chiesi found to have breached ABPI Code

Privately-held Italian drugmaker Chiesi Farmaceutici has been publicly reprimanded for providing inaccurate…

Chiesi’s stem cell therapy approved in Europe

Chiesi’s Holoclar has become the first stem cell therapy to get the green light in Europe, gaining conditional approval from the European Commission. The therapy – manufactured by Holostem Advance...

Pharmaxis partners cystic fibrosis drug Bronchitol with Chiesi in the US

After struggling to bring the product to market on its own, Pharmaxis Ltd. secured Chiesi Farmaceutici SPA as its exclusive US partner for the cystic fibrosis candidate Bronchitol (mannitol), which is...

Chiesi rapped for ABPI code breach

Chiesi made its sales reps go through a ‘tick-box’ compliance training exercise to get the pharma industry regulator ‘off its back’ – according to a public reprimand by the industry standard...

Chiesi Farmaceutici S.p.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Recently added to the BioPortfolio report store, Chiesi Farmaceutici S.p.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report is a new report from MarketLine ...

Chiesi reprimanded again over Fostair drug

Chiesi has been reprimanded after it breached the ABPI’s Code of Practice for its promotion of asthma inhaler Fostair. The PMCPA notes that misleading claims regarding Fostair (formoterol/beclometas...

uniQure, Chiesi sales and marketing update

Holoclar® - The first stem-cell therapy approved for medical use in Europe

Dr Andreas Chiesi, CEO, Holostem Terapie Avanzate S.r.l

PubMed Articles [2379 Associated PubMed Articles listed on BioPortfolio]

Reduction of Campylobacter jejuni in Broiler Chicken by Successive Application of Group II and Group III Phages.

Bacteriophage treatment is a promising tool to reduce Campylobacter in chickens. Several studies have been published where group II or group III phages were successfully applied. However, these two gr...

Enzymatic Debridement in Necrotizing Pancreatitis.

Multiple organ failure and pancreatic necrosis are the factors that determine prognosis in acute pancreatitis attacks. We investigated the effects of collagenase on the debridement of experimental pan...

When talking makes you feel like a group: The emergence of group-based emotions.

Group-based emotions are emotional reactions to group concerns and have been shown to emerge when people appraise events while endorsing a specific social identity. Here we investigate whether discuss...

Commentary on "Toward Understanding and Treating Violence in America: Some Contributions From Group Dynamic and Group Therapy Perspectives".

Commentary on "Toward Understanding and Treating Violence in America: Some Contributions From Group Dynamic and Group Therapy Perspectives".

Clinical Trials [1687 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Does Cognitive Rehabilitation Demonstrate Benefits in the Group Setting With People Whom Have Experienced Brain Injury?

The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...

Short Term Group Therapy for OCD

Assessing OCD before and after group therapy

Early Group Based Parental Support Within Child Health Service - Group Leadership

All parents in Sweden are offered group based parental support within Child Health Service (CHS) but only 40% participate. Nurses feel insecure in their group leadership and express a need...

Psychological Prevention of Internalizing Disorders

The purpose of this study is to determine whether cognitive-behavioral group prevention (CBT-G) for german children is effective and to what extent parental group training moderates outcom...

Companies [1477 Associated Companies listed on BioPortfolio]

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Chiesi Group" on BioPortfolio

We have published hundreds of Chiesi Group news stories on BioPortfolio along with dozens of Chiesi Group Clinical Trials and PubMed Articles about Chiesi Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Group Companies in our database. You can also find out about relevant Chiesi Group Drugs and Medications on this site too.


Advertisement
 

Relevant Topic

Bioethics
Latest News Clinical Trials Research Drugs Reports Corporate
Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...

Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record